Latest Research And Development News

Agrimin Limited has ceased capital allocation to its Mackay Potash Project following a strategic review, while advancing exploration efforts in the promising West Arunta region.

Ardea Resources has made disciplined progress on its Kalgoorlie Nickel Project’s Definitive Feasibility Study, supported by renewed Major Project Status and full funding from a Japanese consortium. Completion is on track for mid-2026 amid robust resource updates and strategic partnerships.

Patrys Limited has expanded its therapeutic portfolio by acquiring Reliis Pty Ltd, adding a proprietary injectable asset targeting delirium with near-term clinical milestones. This strategic move complements its existing biologics platform and strengthens its financial position.

Parkway Corporate Limited reported steady revenues of $3.64 million for Q2 FY26 and breakeven EBITDA, while progressing its flagship Queensland Brine Management Complex project with a secured site and lodged development application.

Argent BioPharma has restructured its acquisition of AusCann assets to sharpen its clinical focus and secured a substantial A$11 million financing facility, positioning itself for growth in 2026.

First Graphene Limited has reported a landmark quarter with a 156% surge in customer cash receipts and a major industrial-scale production of graphene-enhanced cement, signalling a pivotal step in commercialising graphene across multiple sectors.

Rent.com.au has reported its strongest quarter yet, breaking the $1 million revenue mark with a significant surge in recurring revenue driven by its RentPay and RentBond products.

Skin Elements Limited has marked a pivotal quarter with a $2.5 million capital raise and successful product evaluations, setting the stage for commercial rollout of its natural biotechnology range in 2026.

Inhalerx Limited reported a $628,000 cash burn in the December quarter while securing substantial funding facilities to advance its clinical trials. The company’s cash position and financing arrangements suggest a runway extending over 80 quarters at current spending levels.

Neurizon Therapeutics has locked in a $6 million cash rebate from the Australian Government’s R&D Tax Incentive, underpinning its upcoming HEALEY ALS Platform Trial with first patient dosing slated for early 2026.

Syntara Limited has made significant strides in its clinical pipeline, launching new trials and receiving key regulatory designations, positioning 2026 as a pivotal year for the company.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.